We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
-$11.8M
Cap. Flow
-$571K
Cap. Flow %
-0.02%
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.47M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.05M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.91M
4
BSX icon
Boston Scientific
BSX
+$6.1M
5
GILD icon
Gilead Sciences
GILD
+$5.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.7M
2
ILMN icon
Illumina
ILMN
+$12.7M
3
ELV icon
Elevance Health
ELV
+$10.4M
4
CNC icon
Centene
CNC
+$6.81M
5
AGN
Allergan plc
AGN
+$6.78M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Real Estate 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
51
BeOne Medicines Ltd
ONC
$32.8B
$11.8M 0.48%
94,889
– –
ALNY icon
52
Alnylam Pharmaceuticals
ALNY
$27.5B
$11.7M 0.48%
161,372
+27,914
+21% +$2.14M
GWPH
53
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$11.1M 0.45%
64,499
+29,608
+85% +$5.12M
KYNB
54
Kyntra Bio
KYNB
$27.2M
$11M 0.45%
9,773
+2,743
+39% +$3M
AMRN
55
Amarin Corp
AMRN
$299M
$10.7M 0.44%
27,665
-2,903
-9% -$1.06M
MDCO
56
DELISTED
Medicines Co
MDCO
$10.1M 0.41%
278,092
-15,300
-5% -$499K
NKTR icon
57
Nektar Therapeutics
NKTR
$2.39B
$10.1M 0.41%
18,912
– –
OHI icon
58
Omega Healthcare
OHI
$15.1B
$10M 0.41%
272,766
-67,500
-20% -$2.46M
JAZZ icon
59
Jazz Pharmaceuticals
JAZZ
$15.9B
$9.62M 0.39%
67,471
– –
ZBH icon
60
Zimmer Biomet
ZBH
$18.2B
$9.38M 0.38%
82,044
– –
SBRA icon
61
Sabra Healthcare REIT
SBRA
$5.34B
$9.18M 0.37%
466,247
– –
BPMC
62
DELISTED
Blueprint Medicines
BPMC
$8.96M 0.37%
94,976
-20,744
-18% -$1.71M
GSK icon
63
GSK
GSK
$104B
$8.75M 0.36%
174,960
– –
ESPR
64
DELISTED
Esperion Therapeutics
ESPR
$8.59M 0.35%
184,607
– –
ABMD
65
DELISTED
Abiomed Inc
ABMD
$8.52M 0.35%
32,716
+8,730
+36% +$2.32M
ASND icon
66
Ascendis Pharma A/S
ASND
$16B
$8.48M 0.35%
73,647
+12,287
+20% +$1.47M
CRSP icon
67
CRISPR Therapeutics
CRSP
$4.73B
$8.4M 0.34%
178,348
– –
IONS icon
68
Ionis Pharmaceuticals
IONS
$8.6B
$8.2M 0.33%
127,598
+17,878
+16% +$1.26M
XBI icon
69
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$7.81M 0.32%
89,022
– –
ALGN icon
70
Align Technology
ALGN
$12.1B
$7.74M 0.32%
28,278
– –
XLRN
71
DELISTED
Acceleron Pharma
XLRN
$7.74M 0.32%
188,388
– –
XRAY icon
72
Dentsply Sirona
XRAY
$2.68B
$7.41M 0.3%
126,921
-29,600
-19% -$1.59M
STRO icon
73
Sutro Biopharma
STRO
$401M
$7.3M 0.3%
64,127
– –
TEVA icon
74
Teva Pharmaceuticals
TEVA
$40.8B
$7.25M 0.3%
785,851
-105,138
-12% -$1.27M
AGIO icon
75
Agios Pharmaceuticals
AGIO
$1.79B
$7.25M 0.3%
145,342
+53,566
+58% +$2.86M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tekla Capital Management held 207 positions worth $2.45B, down 0.48% from $2.46B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2019 filing shows 13 new, 45 increased, 58 reduced and 10 closed positions. Its largest new stake was Alcon: 55,369 shares worth $3.44M. The largest sale was Biogen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2019 buy was Alcon: 55,369 shares worth $3.44M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $8.47M increase.
  • Tekla Capital Management's biggest Q2 2019 reduction was Biogen, cutting an estimated $20.7M.
  • Tekla Capital Management fully exited Centene in Q2 2019, selling an estimated $6.81M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2019.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q2 2019.
  • Tekla Capital Management's portfolio value fell 0.48% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.